Best Genomics Companies in Paris, France
The 45 best Genomics companies in Paris, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: DNA Script.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Paris
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNA Script Developer of benchtop DNA printer for nucleic acid synthesis | $315M | 35 mo ago | 202 | Xavier Godron Co-founder & CTO | WordPress Block EditorWordPressBugHerd+30 | Top 10M | 334 patents Patents concentrated in chemistry & materials | — |
| 2 | HiFiBiO Provider of a technology platform for the discovery of antibody-based drugs | $180M | 62 mo ago | 75 | Liang Schweizer Founder | — | — | 36 patents Patents concentrated in chemistry & materials | — |
| 3 | SparingVision Developer of drugs using gene therapy to treat retinitis pigmentosa | $128M | 47 mo ago | 41 | Jose Sahel Co-Founder | WordPress Block EditorwpBakeryWordPress+24 | Top 50M | 37 patents Neuroprotective gene and protein therapies for retinal degenerative diseases | 1 award |
| 4 | GenSight Biologics Developer of viral vector-based gene therapies for retinal neurodegenerative diseases 55AI top 15%Product top 19%Funding top 20%Patents top 33% All 11 signals ▾AItop 15% Producttop 19% Fundingtop 20% Patentstop 33% Moattop 38% Innovationtop 43% Globaltop 47% Growthbottom 47% Marketbottom 41% Newsbottom 33% Techbottom 31% AI: Holds AI/ML patents (G06N-family CPC) Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 55/100 | $77M | 5 mo ago | 23 | — | WordPressMySQLPHP+12 | Top 5M | 89 patents Optogenetic gene‑therapy vectors and precision light‑delivery devices for retinal treatments | — |
| 5 | Eligo Bioscience Developer of in vivo gene editing technology for microbiome modulation 48Patents top 16%Innovation top 19%Moat top 29%Funding top 36% All 11 signals ▾Patentstop 16% Innovationtop 19% Moattop 29% Fundingtop 36% Techtop 48% Talentbottom 49% Growthbottom 48% Globalbottom 44% Marketbottom 42% Fin. healthbottom 27% Newsbottom 22% Patents: 199 patents matched (strict assignee match) · 142 filings since 2022 vs 57 in 2017-21 Innovation: 199 patents (top 13% of patent-holders) · 142 filings since 2022 vs 57 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $52M | 15 mo ago | 44 | Xavier Duportet Co-Founder & CEO | WordPressVisual ComposerwpBakery+26 | Top 10M | 199 patents Phage‑based diagnostics and therapeutics targeting Cutibacterium acnes skin microbiome. | 1 job opening |
| 6 | Da Volterra Developer of products to prevent bacterial infections triggered by antibiotic therapies | $24M | 107 mo ago | 16 | — | — | — | 163 patents Probiotic yeast and oral formulations delivering antibiotic‑inactivating enzymes and gut adsorbents | — |
| 7 | DeepLife Provider of AI-based drug discovery and omics analysis tool for researchers 37AI top 22%Funding top 40%Moat top 45%Patents top 48% All 8 signals ▾AItop 22% Fundingtop 40% Moattop 45% Patentstop 48% Innovationtop 49% Talentbottom 49% Globalbottom 39% Marketbottom 24% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $16.4M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $16M | 20 mo ago | 10 | Jonathan Baptista Co-Founder & CEO | — | — | 4 patents AI-driven graph analytics and generative digital twin simulation for complex system modeling | 1 award |
| 8 | Meiogenix Developer of novel breeding technologies for crop plants | $13M | 56 mo ago | 7 | Luc Mathis CEO | WebflowGSAPMicrosoft Advertising+10 | Top 50M | 39 patents CRISPR‑based tools for engineered meiotic recombination and genome editing | — |
| 9 | Rarecells Developer of noninvasive tests for earlier cancer diagnoses | $13M | 56 mo ago | 22 | — | — | — | 20 patents Rare cell isolation, filtration, and liquid biopsy biomarker analysis for cancer diagnostics | 1 partnership |
| 10 | Annapurna Therapeutics Developer of adeno-associated virus (AAV) mediated gene therapies for rare diseases | $12M | 148 mo ago | — | Amber Salzman ex-CEO | — | — | — | — |
| 11 | WhiteLab Genomics Provider of drug discovery and development platform | $10M | 47 mo ago | 29 | David Del Bourgo CEO co-founder | SkolengoSentryApple iCloud Mail+20 | Top 50M | 4 patents ML-driven phenotype prediction and cell surface protein identification for genomics applications. | — |
| 12 | PathoQuest Provider of next-generation sequencing for microbiology testing | $10M | 57 mo ago | 48 | — | WordPressMySQLPHP+29 | Top 50M | 68 patents Microbial viability assays and anellovirus quantification for clinical immune-status diagnostics | — |
| 13 | Scipio Bioscience Develops sample preparation solutions | $8M | 38 mo ago | 44 | Pierre Walrafen Co-Founder & CEO | — | — | 19 patents Single-cell spatial omics via hydrogel trapping and barcoding technologies | — |
| 14 | Biomemory Online platform offering bio-digital data storage solutions | $5M | 20 mo ago | 10 | Erfane Arwani Co-Founder & CEO | WebflowGSAPLenis+15 | Top 50M | — | — |
| 15 | One Biosciences Developer of single-cell therapeutics solutions to treat multiple health disorders | $5M | 13 mo ago | — | Celine Vallot Co-Founder | WordPressMySQLPHP+7 | Top 10M | — | 1 award |
| 16 | Brink Therapeutics Developer of cell and gene therapies to treat various diseases | $4M | 16 mo ago | — | Jonathan Naccache Co-Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+12 | Top 50M | — | — |
| 17 | Epigene Labs Developer of drugs through precision oncology | $3M | 48 mo ago | 25 | Akpeli Nordor Co-Founder | WordPressMySQLPHP+22 | Top 50M | — | — |
| 18 | Minos Biosciences Developer of a sequencing-based multi-omic analysis device | $2M | 64 mo ago | 11 | Hubert Geisler Co-founder & Head of Microfluidics | — | — | — | — |
| 19 | En Carta Developer of molecular diagnostic tests for infectious diseases | $2M | 27 mo ago | 3 | Margot Karlikow Co-Founder | — | — | — | — |
| 20 | GreenTropism Provider of software components for mainstream and industrial spectroscopy | $1M | 108 mo ago | 13 | Anthony Boulanger Founder & CEO | — | — | 31 patents SERS-based spectroscopic detection of pathogens in biological fluids | — |
| 21 | Millidrop Provider of cell culture machines based on milli fluidics technology for bacteriological research | $1M | 95 mo ago | 5 | — | — | — | — | — |
| 22 | Brain Vectis Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease | $1M | 119 mo ago | 5 | — | — | — | — | — |
| 23 | NeoNeuro Provider of aptamer-based molecular diagnostics for Alzheimer's Disease | $363K | 71 mo ago | — | Gregory Penner Founder & President | — | — | 6 patents Aptamer-based biomarker discovery for early Alzheimer's disease diagnostics | — |
| 24 | Plantik Biosciences Developer of plant engineering workflow to create climate-resilient and thermotolerant plants | $100K | 27 mo ago | 6 | Aditya Nayak Co-Founder & CTO | Cart FunctionalitySquarespace CommerceSquarespace+10 | Top 50M | 2 patents Plant genome editing technologies for precise genetic modifications | — |
Top 12 Genomics companies in Paris
#1
Public · Paris, Ile de France · founded 2011 · 23 employees$76.6Mraised▾
Developer of viral vector-based gene therapies for retinal neurodegenerative diseases. The company develops innovative approaches to prevent retinal degeneration in selected pathological conditions, to restore vision in patients suffering from very low vision or blindness. Its lead product candidates include GS010, an AAV2 containing the human wild-type ND4 gene for the treatment of Leber Hereditary Optic Neuropathy associated with a mutation in the ND4 gene, and GS030 which comprises a gene encoding a photoactivatable channelrhodopsin for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration.
- Mar 2026Post IPO$2M
- Dec 2025Post IPO$3.4M
- Nov 2025Post IPO$2.3M
- Oct 2025Post IPO$4.3M
#2
Series B · Paris, Ile de France · founded 2014 · 44 employees$52.3Mraised▾
Developer of in vivo gene editing technology for microbiome modulation. The company offers a platform to edit the microbiome's gene repertoire. This platform aims to address diseases triggered or aggravated by specific bacterial genes. The technology targets the interactions between the microbiome and the host's immune system.
- May 2025Grant (prize money)$5M
- Nov 2023Series B$30.1M
- Mar 2022Grant (prize money)$55.7K
- Apr 2019Grant (prize money)$3.1M
#3
Series A · Paris, Ile de France · founded 2020$5Mraised▾
Developer of single-cell therapeutics solutions to treat multiple health disorders. The company's proprietary platform uses single-cell RNA and DNA sequencing that helps to analyze disease-causing agents and provides treatment solutions. The company has developed single-cell computational software for the analysis of genomic data.
- Jul 2025Series A$17.4M
- Sep 2022Series A$5M
#4
Series C · Paris, Ile de France · founded 2014 · 202 employees$315Mraised▾
DNA script is a developer of a benchtop DNA printer powered by enzymatic technology for nucleic acid syntheis. It is offering a benchtop DNA printer that provides outsourced chemical-based DNA synthesis through enzymatic synthesis technology to synthesize DNA.
- Sep 2023Grant (prize money)$4.3M
- Jan 2022Series C$35M
- Oct 2021Series C$165M
- Sep 2021Grant (prize money)$280K
#5
Series A · Paris, Ile de France · founded 2019 · 10 employees$16.4Mraised▾
Provider of AI-based drug discovery and omics analysis tool for researchers. The company has developed tools that are AI-enabled for the process of drug discovery. The tool assists in provided insights for target protein for the drug for an individual patient. The tools use machine learning technology to identify molecular triggers for the drug and target identification. It has features to process biological data, tools for genomic screening, and more.
- Dec 2024Series A$10.5M
- Oct 2022Series A$5.9M
#6
Seed · Paris, Ile de France · founded 2024$4Mraised▾
Developer of cell and gene therapies to treat various diseases. The company is developing next-generation recombinases ultra-precise and efficient enzymes that surpass CRISPR-Cas9 to revolutionize cell and gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.
- Apr 2025Seed$4M
#7
Series A · Paris, Ile de France · founded 2021 · 10 employees$5.2Mraised▾
Online platform offering bio-digital data storage solutions. The platform is developing a petrol-free DNA synthesis and copy process based on synthetic biology for data storage. It also allows the production of long, bio-sourced, biocompatible, and bio-secure DNA fragments that can be stored as inert polymers for thousands of years without any energy input.
- Dec 2024Series A$18M
- Nov 2022Seed$5.2M
#8
Series B · Paris, Ile de France · founded 2016 · 41 employees$128.1Mraised▾
Developer of drugs using gene therapy to treat retinitis pigmentosa. The company discovers and develops genetic medicine which is used to prevent the degeneration of cones cells in the retina to treat inherited retinal diseases. The company develops a single-injection dosage form for gene therapy.
- Sep 2022Series B$75.5M
- Jul 2021Grant (prize money)$59.4K
- Oct 2020Series A$52.5M
- Aug 2019Grant (prize money)$2.7M
#9
Series D · Paris, Ile de France · founded 2013 · 75 employees$179.5Mraised▾
Provider of a technology platform for the discovery of antibody-based drugs. The platform combines high throughput, single-cell, functional-based screening of entire B cell (Ab producing cells) populations with next-generation sequencing and rapid DNA synthesis for rare antibody drugs.
- Jun 2021Series D$75M
- Aug 2019Series C$67M
- May 2018Series B$37.5M
- Series A—
#10
Series A · Paris, Ile de France · founded 2017 · 44 employees$7.9Mraised▾
Scipio Bioscience is engaged in the development of sample preparation solutions for single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular, transcriptomics.
- 2023Grant (prize money)—
- Feb 2020Series A$6.5M
- Nov 2017Seed$1.4M
#11
Seed · Paris, Ile de France · founded 2020 · 3 employees$1.6Mraised▾
Developer of molecular diagnostic tests for infectious diseases. It offers PCR-based diagnostic assays that detect attomolar concentrations of pathogens in samples like saliva, nose swabs or interstitial fluid. It offers diagnostics kit for detection of the bacterial carrier of Lyme disease, SARS-CoV-2, Zika and Chikungunya Virus.
- May 2024Seed$1.6M
#12
Series A · Paris, Ile de France · founded 2019 · 29 employees$10.2Mraised▾
Provider of drug discovery and development platform. The platform utilizes AI technology to predict and identify drug candidate molecules for therapeutic purposes.
- Sep 2022Series A$10.1M
- 2022Seed$500K
- Jul 2019Grant (prize money)$44.8K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Paris is moving
A read on the academic research around Bioinformatics in Paris — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 336 papers.
- Assistance Publique – Hôpitaux de Paris112
- Université Paris Cité64
- Université Paris-Saclay55
- AgroParisTech37
- CEA Paris-Saclay33
- Gene1→15
- Transcriptome1→15
- Gene expression profiling1→7
- Immune system1→5
- Identification (biology)1→4
- Transcriptome1→6
- Gene3→5
- Microbiome1→3
- Disease8
- Gene6
- Identification (biology)5
- Metagenomics4
- Computational biology3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.